DSP-2230

DSP-2230 is a selective small-molecule Na_v1.7 and Na_v1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.^[1][2] As of June 2014, it is in phase I/phase II clinical trials.^[1][2]

DSP-2230

Clinical data
Routes of administration	By mouth
Identifiers
IUPAC name (2S)-2-[[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]amino]propanamide
CAS Number	1233231-30-5 Y
UNII	LSY2D22FBK
ChEMBL	ChEMBL3545012
Chemical and physical data
Formula	C20H20F3N5O2
Molar mass	419.408 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC1=CC(OC2=CC=C(N=C3CN([C@@H](C(N([H])[H])=O)C)[H])C(N3C4CCC4)=N2)=CC(F)=C1F
InChI InChI=1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m1/s1 Key:HHXCJIMPEJSJTG-SNVBAGLBSA-N

See also

• List of investigational analgesics